Ionis Pharmaceuticals Announces Phase 3 NEURO-TTR Study of Inotersen (IONIS-TTR Rx) Meets Both Primary Endpoints

Webcast to Discuss Results May 15, 2017 at 8:30 am ET CARLSBAD, Calif., May 15, 2017 -- (Healthcare Sales & Marketing Network) -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that the Phase 3 NEURO-TTR study of inotersen (IONIS-TTRRx) in ... Biopharmaceuticals Ionis Pharmaceuticals, inotersen, IONIS-TTRRx, familial amyloid polyneuropathy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news